Almirall, S.A. ALM.MC Stock
Almirall, S.A. Price Chart
Almirall, S.A. ALM.MC Financial and Trading Overview
| Almirall, S.A. stock price | 8.26 EUR |
| Previous Close | 8 EUR |
| Open | 0 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 0 - 0 EUR |
| 52 Week Range | 0 - 11.33 EUR |
| Volume | 44.85K EUR |
| Avg. Volume | 236.58K EUR |
| Market Cap | 1.47B EUR |
| Beta (5Y Monthly) | 0.408812 |
| PE Ratio (TTM) | 49.8125 |
| EPS (TTM) | -0.2 EUR |
| Forward Dividend & Yield | 0.18 (2.28%) |
| Ex-Dividend Date | May 12, 2023 |
| 1y Target Est | 13.48 EUR |
ALM.MC Valuation Measures
| Enterprise Value | 2.65B EUR |
| Trailing P/E | 49.8125 |
| Forward P/E | 17.326086 |
| PEG Ratio (5 yr expected) | -3.35 |
| Price/Sales (ttm) | 1.7003931 |
| Price/Book (mrq) | 1.880604 |
| Enterprise Value/Revenue | 3.06 |
| Enterprise Value/EBITDA | 14.633 |
Trading Information
Almirall, S.A. Stock Price History
| Beta (5Y Monthly) | 0.408812 |
| 52-Week Change | -18.67% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11.33 EUR |
| 52 Week Low | 0 EUR |
| 50-Day Moving Average | 8.7 EUR |
| 200-Day Moving Average | 9.04 EUR |
ALM.MC Share Statistics
| Avg. Volume (3 month) | 236.58K EUR |
| Avg. Daily Volume (10-Days) | 367.13K EUR |
| Shares Outstanding | 184.92M |
| Float | 125.82M |
| Short Ratio | N/A |
| % Held by Insiders | 59.67% |
| % Held by Institutions | 15.32% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 1.1625 |
| Last Split Factor | 47:46 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -0.97% |
| Operating Margin (ttm) | 6.71% |
| Gross Margin | 78.16% |
| EBITDA Margin | 20.91% |
Management Effectiveness
| Return on Assets (ttm) | 1.71% |
| Return on Equity (ttm) | -0.63% |
Income Statement
| Revenue (ttm) | 866.75M EUR |
| Revenue Per Share (ttm) | 4.03 EUR |
| Quarterly Revenue Growth (yoy) | 1.50% |
| Gross Profit (ttm) | 681.46M EUR |
| EBITDA | 181.25M EUR |
| Net Income Avi to Common (ttm) | -8419000 EUR |
| Diluted EPS (ttm) | 0.16 |
| Quarterly Earnings Growth (yoy) | -62.29% |
Balance Sheet
| Total Cash (mrq) | 197.8M EUR |
| Total Cash Per Share (mrq) | 0.64 EUR |
| Total Debt (mrq) | 360.4M EUR |
| Total Debt/Equity (mrq) | 27.3 EUR |
| Current Ratio (mrq) | 2.191 |
| Book Value Per Share (mrq) | 4.238 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 153.7M EUR |
| Levered Free Cash Flow (ttm) | 46.4M EUR |
Profile of Almirall, S.A.
| Country | Spain |
| State | N/A |
| City | Barcelona |
| Address | Ronda Del General Miter, 151 |
| ZIP | 08022 |
| Phone | 34 93 291 30 00 |
| Website | https://www.almirall.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 1814 |
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Q&A For Almirall, S.A. Stock
What is a current ALM.MC stock price?
Almirall, S.A. ALM.MC stock price today per share is 8.26 EUR.
How to purchase Almirall, S.A. stock?
You can buy ALM.MC shares on the MCE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Almirall, S.A.?
The stock symbol or ticker of Almirall, S.A. is ALM.MC.
Which industry does the Almirall, S.A. company belong to?
The Almirall, S.A. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Almirall, S.A. have in circulation?
The max supply of Almirall, S.A. shares is 209.18M.
What is Almirall, S.A. Price to Earnings Ratio (PE Ratio)?
Almirall, S.A. PE Ratio is now.
What was Almirall, S.A. earnings per share over the trailing 12 months (TTM)?
Almirall, S.A. EPS is -0.2 EUR over the trailing 12 months.
Which sector does the Almirall, S.A. company belong to?
The Almirall, S.A. sector is Healthcare.
Almirall, S.A. ALM.MC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}